Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using <sup>177</sup>Lu-FAP-2286: First-in-Humans Results

P. Baum, Richard; Schuchardt, Christiane; Singh, Aviral; Chantadisai, Maythinee; Robiller, F; Zhang, Jingjing; Müeller, Dirk; Eismant, Alexander; Almaguel, Frankis; Zboralski, Dirk; Osterkamp, Frank; Hoehne, Aileen; Reineke, Ulrich; Smerling, Christiane; Kulkarni, Harshad

doi:10.2967/jnumed.120.259192

Public

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results

Published in Journal of Nuclear Medicine • Jun 24, 2021

Authors:

Richard P. Baum

Christiane Schuchardt

Aviral Singh

Abstract

Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides for theranostic applications. We present the first-in-human results using 177Lu-FAP-2286 for p...

Subject

Radionuclide therapy

Medicine

Nuclear medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!